Literature DB >> 15577537

Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations.

Kim M Wilson1, Elizabeth I M Johnson, Hayley A Croom, Kim M Richards, Larissa Doughty, Philip H Cunningham, Bruce E Kemp, Bernard M Branson, Elizabeth M Dax.   

Abstract

OBJECTIVE: To identify a specific marker of recent HIV-1 infection.
DESIGN: The humoral immune response in individuals recently infected with HIV-1 was followed by analysing the antibody isotype-specific response generated to HIV-1 antigens in sequential samples collected during and following seroconversion.
METHODS: Antibody isotype-specific HIV-1 Western blots were analysed to identify interactions indicative of recent HIV-1 infection. These responses were further quantified using an antibody isotype-specific enzyme-linked immunoabsorbent assay based on recombinant HIV-1 antigens.
RESULTS: During maturation of the immune response to HIV-1 infection, a rapid and enduring IgG1 isotype response was seen to all the major proteins transcribed by env, gag and pol. An early transient peak of IgG3 reactivity to p24 was observed over an interval of approximately 1-4 months following HIV-1 infection. The presence of IgG3 reactivity to p24 permitted established infection to be distinguished from recently infected individuals during this time period.
CONCLUSION: An assay for anti-p24 IgG3 reactivity would provide an estimate of the incidence of HIV infection that may be applicable for epidemiological surveys as well as for monitoring new infections during vaccine trials and for managing treatment programmes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15577537     DOI: 10.1097/00002030-200411190-00005

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  23 in total

1.  Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection.

Authors:  Nicole L Yates; Judith T Lucas; Tracy L Nolen; Nathan A Vandergrift; Kelly A Soderberg; Kelly E Seaton; Thomas N Denny; Barton F Haynes; Myron S Cohen; Georgia D Tomaras
Journal:  AIDS       Date:  2011-11-13       Impact factor: 4.177

2.  A comprehensive evaluation of the proficiency testing program for the HIV-1 BED incidence assay.

Authors:  Trudy Dobbs; Xin Liu; Rebecca Anderson; John Nkengasong; Bharat S Parekh
Journal:  J Clin Microbiol       Date:  2011-08-10       Impact factor: 5.948

3.  Estimating HIV Incidence in Populations Using Tests for Recent Infection: Issues, Challenges and the Way Forward.

Authors:  Timothy D Mastro; Andrea A Kim; Timothy Hallett; Thomas Rehle; Alex Welte; Oliver Laeyendecker; Tom Oluoch; Jesus M Garcia-Calleja
Journal:  J HIV AIDS Surveill Epidemiol       Date:  2010-01-01

4.  Detection of IgG3 antibodies specific to the human immunodeficiency virus type 1 (HIV-1) p24 protein as marker for recently acquired infection.

Authors:  I F T Viana; D F Coêlho; M L Palma; E J M Nascimento; G Gu; L F O Lima; L Foti; M A Krieger; C Pilcher; C E Calzavara-Silva; R B Mailliard; C R Rinaldo; R Dhalia; E T A Marques
Journal:  Epidemiol Infect       Date:  2018-06-21       Impact factor: 2.451

5.  Decreased specificity of an assay for recent infection in HIV-1-infected patients on highly active antiretroviral treatment: implications for incidence estimates.

Authors:  Antoine Chaillon; Stéphane Le Vu; Sylvie Brunet; Guillaume Gras; Frédéric Bastides; Louis Bernard; Laurence Meyer; Francis Barin
Journal:  Clin Vaccine Immunol       Date:  2012-06-20

Review 6.  Diagnosis of Human Immunodeficiency Virus Infection.

Authors:  Bharat S Parekh; Chin-Yih Ou; Peter N Fonjungo; Mireille B Kalou; Erin Rottinghaus; Adrian Puren; Heather Alexander; Mackenzie Hurlston Cox; John N Nkengasong
Journal:  Clin Microbiol Rev       Date:  2018-11-28       Impact factor: 26.132

7.  The effect of viral suppression on cross-sectional incidence testing in the johns hopkins hospital emergency department.

Authors:  Oliver Laeyendecker; Richard E Rothman; Charlamaine Henson; Bobbi Jo Horne; Kerunne S Ketlogetswe; Chadd K Kraus; Judy Shahan; Gabor D Kelen; Thomas C Quinn
Journal:  J Acquir Immune Defic Syndr       Date:  2008-06-01       Impact factor: 3.731

8.  Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions.

Authors:  Erin E Verity; Dimitra Zotos; Kim Wilson; Catherine Chatfield; Victoria A Lawson; Dominic E Dwyer; Anthony Cunningham; Jennifer Learmont; Wayne Dyer; John Sullivan; Melissa Churchill; Steven L Wesselingh; Dana Gabuzda; Paul R Gorry; Dale A McPhee
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

9.  Computational analysis of antibody dynamics identifies recent HIV-1 infection.

Authors:  Kelly E Seaton; Nathan A Vandergrift; Aaron W Deal; Wes Rountree; John Bainbridge; Eduard Grebe; David A Anderson; Sheetal Sawant; Xiaoying Shen; Nicole L Yates; Thomas N Denny; Hua-Xin Liao; Barton F Haynes; Merlin L Robb; Neil Parkin; Breno R Santos; Nigel Garrett; Matthew A Price; Denise Naniche; Ann C Duerr; Sheila Keating; Dylan Hampton; Shelley Facente; Kara Marson; Alex Welte; Christopher D Pilcher; Myron S Cohen; Georgia D Tomaras
Journal:  JCI Insight       Date:  2017-12-21

Review 10.  HIV-1-specific antibody responses during acute and chronic HIV-1 infection.

Authors:  Georgia D Tomaras; Barton F Haynes
Journal:  Curr Opin HIV AIDS       Date:  2009-09       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.